home / stock / meip / meip short
Short Information | MEI Pharma Inc. (NASDAQ:MEIP)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 35,985 |
Total Actual Volume | 255,724 |
Short Trends | |
---|---|
Cover Days | 19 |
Short Days | 0 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 1,799 |
Average Short Percentage | 15.79% |
Is there a MEIP Short Squeeze or Breakout about to happen?
See the MEIP Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-16-2024 | $2.78 | $2.81 | $2.88 | $2.78 | 14,426 | 2,291 | 15.88% |
07-15-2024 | $2.93 | $2.84 | $2.93 | $2.78 | 15,650 | 1,407 | 8.99% |
07-12-2024 | $2.8344 | $2.9 | $2.9001 | $2.8344 | 15,228 | 2,924 | 19.2% |
07-11-2024 | $2.78 | $2.82 | $2.83 | $2.78 | 7,682 | 906 | 11.79% |
07-10-2024 | $2.78 | $2.79 | $2.815 | $2.78 | 10,111 | 1,774 | 17.55% |
07-09-2024 | $2.82 | $2.81 | $2.84 | $2.78 | 7,819 | 1,311 | 16.77% |
07-08-2024 | $2.7801 | $2.82 | $2.82 | $2.7801 | 4,818 | 1,066 | 22.13% |
07-05-2024 | $2.81 | $2.8 | $2.83 | $2.78 | 11,485 | 1,508 | 13.13% |
07-03-2024 | $2.825 | $2.82 | $2.825 | $2.8 | 1,672 | 194 | 11.6% |
07-02-2024 | $2.84 | $2.8 | $2.855 | $2.78 | 44,634 | 2,456 | 5.5% |
07-01-2024 | $2.84 | $2.85 | $2.9 | $2.84 | 15,860 | 1,687 | 10.64% |
06-28-2024 | $2.95 | $2.91 | $2.9899 | $2.9 | 15,456 | 553 | 3.58% |
06-27-2024 | $2.83 | $2.95 | $2.95 | $2.83 | 17,947 | 2,431 | 13.55% |
06-26-2024 | $2.86 | $2.86 | $2.91 | $2.83 | 7,459 | 1,752 | 23.49% |
06-25-2024 | $2.78 | $2.86 | $2.87 | $2.78 | 18,999 | 6,431 | 33.85% |
06-24-2024 | $2.82 | $2.78 | $2.8724 | $2.78 | 15,257 | 918 | 6.02% |
06-21-2024 | $2.7915 | $2.86 | $2.86 | $2.7915 | 8,146 | 914 | 11.22% |
06-20-2024 | $2.82 | $2.84 | $2.8699 | $2.78 | 5,145 | 772 | 15% |
06-18-2024 | $2.855 | $2.82 | $2.855 | $2.82 | 10,097 | 1,380 | 13.67% |
06-17-2024 | $2.86 | $2.88 | $2.91 | $2.82 | 7,833 | 3,310 | 42.26% |
News, Short Squeeze, Breakout and More Instantly...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...